ENO1 Antibody - #DF6191

(4)   (12)  
Product: ENO1 Antibody
Catalog: DF6191
Description: Rabbit polyclonal antibody to ENO1
Application: WB IHC IF/ICC
Cited expt.: WB, IHC
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Pig, Bovine, Horse, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 47kDa; 47kD(Calculated).
Uniprot: P06733
RRID: AB_2838157

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:400
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Pig(100%), Bovine(89%), Horse(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)
Clonality:
Polyclonal
Specificity:
ENO1 Antibody detects endogenous levels of total ENO1.
RRID:
AB_2838157
Cite Format: Affinity Biosciences Cat# DF6191, RRID:AB_2838157.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

2 phospho D glycerate hydro lyase; 2-phospho-D-glycerate hydro-lyase; Alpha enolase; Alpha enolase like 1; Alpha-enolase; C myc promoter binding protein; C-myc promoter-binding protein; EC 4.2.1.11; eno1; ENO1L1; ENOA_HUMAN; Enolase 1 (alpha); Enolase 1 (alpha) like 1; Enolase 1; Enolase alpha; MBP 1; MBP-1; MBP1; MBPB1; MPB 1; MPB-1; MPB1; MYC promoter binding protein 1; NNE; Non neural enolase; Non-neural enolase; Phosphopyruvate hydratase; Plasminogen binding protein; Plasminogen-binding protein; PPH; Tau crystallin;

Immunogens

Immunogen:

A synthesized peptide derived from human ENO1, corresponding to a region within C-terminal amino acids.

Uniprot:

P06733(ENOA_HUMAN) >>Visit HPA database.

Gene(ID):
ENO1(2023)
Expression:
P06733 ENOA_HUMAN:

The alpha/alpha homodimer is expressed in embryo and in most adult tissues. The alpha/beta heterodimer and the beta/beta homodimer are found in striated muscle, and the alpha/gamma heterodimer and the gamma/gamma homodimer in neurons.

Description:
Enolase is an important glycolytic enzyme involved in the interconversion of 2-phosphoglycerate to phosphoenolpyruvate. Mammalian enolase exists as three subunits: enolase-1 (α-enolase), enolase-2 (γ-enolase) and enolase-3 (β-enolase) that can form both homo- and heterodimers. Expression of the enolase isoforms differs in a tissue specific manner (1). Enolase-1 plays a key role in anaerobic metabolism under hypoxic conditions and may act as a cell surface plasminogen receptor during tissue invasion (2,3). Abnormal expression of enolase-1 is associated with tumor progression in some cases of breast and lung cancer (4-7). Alternatively, an enolase-1 splice variant (MBP-1) binds the c-myc promoter p2 and may function as a tumor suppressor. For this reason enolase-1 is considered as a potential therapeutic target in the treatment of some forms of cancer (8).
Sequence:
MSILKIHAREIFDSRGNPTVEVDLFTSKGLFRAAVPSGASTGIYEALELRDNDKTRYMGKGVSKAVEHINKTIAPALVSKKLNVTEQEKIDKLMIEMDGTENKSKFGANAILGVSLAVCKAGAVEKGVPLYRHIADLAGNSEVILPVPAFNVINGGSHAGNKLAMQEFMILPVGAANFREAMRIGAEVYHNLKNVIKEKYGKDATNVGDEGGFAPNILENKEGLELLKTAIGKAGYTDKVVIGMDVAASEFFRSGKYDLDFKSPDDPSRYISPDQLADLYKSFIKDYPVVSIEDPFDQDDWGAWQKFTASAGIQVVGDDLTVTNPKRIAKAVNEKSCNCLLLKVNQIGSVTESLQACKLAQANGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQLLRIEEELGSKAKFAGRNFRNPLAK

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Dog
100
Xenopus
100
Chicken
100
Rabbit
100
Bovine
89
Sheep
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Glycolytic enzyme the catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate. In addition to glycolysis, involved in various processes such as growth control, hypoxia tolerance and allergic responses. May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons. Stimulates immunoglobulin production.

MBP1 binds to the myc promoter and acts as a transcriptional repressor. May be a tumor suppressor.

PTMs:

ISGylated.

Lysine 2-hydroxyisobutyrylation (Khib) by p300/EP300 activates the phosphopyruvate hydratase activity.

Subcellular Location:

Cytoplasm. Cell membrane. Cytoplasm>Myofibril>Sarcomere>M line.
Note: Can translocate to the plasma membrane in either the homodimeric (alpha/alpha) or heterodimeric (alpha/gamma) form. ENO1 is localized to the M line.

Nucleus.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

The alpha/alpha homodimer is expressed in embryo and in most adult tissues. The alpha/beta heterodimer and the beta/beta homodimer are found in striated muscle, and the alpha/gamma heterodimer and the gamma/gamma homodimer in neurons.

Family&Domains:

Belongs to the enolase family.

Research Fields

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Genetic Information Processing > Folding, sorting and degradation > RNA degradation.

· Metabolism > Carbohydrate metabolism > Glycolysis / Gluconeogenesis.

· Metabolism > Global and overview maps > Metabolic pathways.

· Metabolism > Global and overview maps > Carbon metabolism.

· Metabolism > Global and overview maps > Biosynthesis of amino acids.

References

1). Pimozide inhibits the growth of breast cancer cells by alleviating the Warburg effect through the P53 signaling pathway. BIOMEDICINE & PHARMACOTHERAPY, 2022 (PubMed: 35658233) [IF=6.9]

Application: WB    Species: Human    Sample: MCF-7 cells

Fig. 3. Pimozide inhibits PKM2 protein and mRNA in both MCF-7 and MDA-MB-231 cells in vitro. (A-B) Cells were treated with the indicated concentrations of Pimozide for 24 h, and the protein expression of glycolytic enzymes in MCF-7(A) and MDA-MB-231(B) cells were determined by Western blot analysis (left panel). Densitometry analysis was performed to assess the glycolytic enzymes protein expression (normalized to β-actin expression), PKM2 decreased significantly compared with untreated cells (right panel). (C-D) The mRNA expression of PKM2 in MCF-7(C) and MDA-MB-231(D) cells untreated or treated with Pimozide was determined by qRT-PCR. GAPDH was used as a control. Data represent mean ± SD from three biological replicates (*p < 0.05, **p < 0.01).
2). Hyperglycemia promotes Snail-induced epithelial-mesenchymal transition of gastric cancer via activating ENO1 expression. Cancer Cell International, 2019 (PubMed: 31889896) [IF=5.8]

Application: IHC    Species: human    Sample: GC and adjacent normal tissues

Fig. 1 |ENO1 was upregulated in GC tissue and was associated with poor prognosis. a, b The expression of ENO1 was determined based on the GSE79973 and TCGA databases. c Western blot analysis detected ENO1 expression in GC and adjacent normal tissues. d Representative ENO1 IHC staining in GC specimens (×200 magnifcation).

Application: WB    Species: human    Sample: GC tissue

Fig. 1 |ENO1 was upregulated in GC tissue and was associated with poor prognosis. a, b The expression of ENO1 was determined based on the GSE79973 and TCGA databases. c Western blot analysis detected ENO1 expression in GC and adjacent normal tissues.
3). Novel long non‐coding RNA CYB561‐5 promotes aerobic glycolysis and tumorigenesis by interacting with basigin in non‐small cell lung cancer. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022 (PubMed: 35064752) [IF=5.3]

Application: WB    Species: Human    Sample: H1299 cells

FIGURE 4 Lnc‐CYB561‐5 promotes aerobic glycolysis in vivo. (A) Cluster analysis of differentially expressed mRNAs in H1299 cells treated with the lnc‐CYB561‐5 knockdown. (B) The top 20 GO enrichment of significantly upregulated genes (fold change > 2, p < 0.05, top 100). (C) Heatmap depicting relative expression of known genes related to glycolysis. (D and E) Measurement of ECARO and CR in H1299 cells treated with the lnc‐CYB561‐5 knockdown. (F) Relative glycolysis rates in H1299 cells, as judged by Seahorse analyses. (G–I) Relative mRNA and protein expression levels of Pfk1, Hk1, Hk2, Eno1, G6pi and Glut1 in H1299 cells. *p < 0.05, **p < 0.01, ***p < 0.001, NS, p > 0.05 vs. the sh‐Ctrl group, n = 5. Data are presented as means ± SEM. Multiple group comparisons were performed using one‐way ANOVA followed by Tukey's post hoc test
4). S100A9 promotes glycolytic activity in HER2-positive breast cancer to induce immunosuppression in the tumour microenvironment. Heliyon, 2023 (PubMed: 36755606) [IF=4.0]

Application: IHC    Species: Human    Sample: HER2+ BRCA tissues

Fig. 2 (A) Enrichment of glycolysis-related genes was significant in S100A9 positive BRCA cases (NES > 1, FDR q-value < 0.001). (B) S100A9 silencing impaired the expression of PGK1, LDHA, and ENO1 in both SK-BR-3 and BT474 cell lines. (C) IHC staining results of HER2+ BRCA tissues confirmed the upregulation of PGK1, LDHA, and ENO1 in S100A9 abundant cases (Scale bar = 100 μm, 200 μm, and 400 μm). (D) ECAR level significantly declined when S100A9 was absent from the SK-BR-3 and BT474 cell lines. (E) lactate production and glucose consumption level significantly declined when S100A9 was absent from the SK-BR-3 and BT474 cell lines. PGK1: Phosphoglycerate kinase 1. LDHA: Lactate dehydrogenase A. ENO1: Enolase α. ECAR: Extracellular acidification rate. S100A9: S100 calcium-binding protein A9. BRCA: Breast cancer. HER2: Human epidermal growth factor receptor 2. NES: Normalised enrichment score. FDR: False discovery rate. IHC:Immunohistochemical staining.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.